VIDEO: Phase 3 trial of atogepant ‘very good news’ for patients with migraine

In this video perspective, Jessica Ailani, MD, discusses results from a phase 3 trial of atogepant for the prevention of migraine that were presented during the American Academy of Neurology annual meeting, which is being held virtually.

The phase 3, multicenter clinical trial looked at three doses of atogepant (AbbVie) — 10 mg, 30 mg and 60 mg — compared with placebo. The trial results demonstrated that “atogepant was an effective treatment at 10 mg, 30 mg and 60 mg and it met its primary endpoint of reduction in monthly migraine days during the duration of the trial,” Ailani told Healio Neurology.

More than 50% of patients experienced a 50% or greater reduction in migraine days, with results “as soon as the first week, which was very exciting for patients,” Ailani said. She believes the results have “a lot of clinical implications” for patients with migraine.

Side effects of atogepant included nausea and constipation, but rates were low and very few patients withdrew because of side effects, according to Ailani. She added that the trial’s results seem to be “very good news” for patients with migraine.

Approval of atogepant would introduce an oral migraine medication “that’s well tolerated and very quickly reduces the frequency of migraine,” Ailani said.